article thumbnail

Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD

SpeedWeed

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. MAPS is now enrolling participants for a further Phase 3 study that will allow another 50 subjects to access this promising new therapy. View original article.

article thumbnail

Cannabis 3.0 Accelerates Access to Consumer and Medical Research

Cannabis Law Report

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK Article: Why Don’t We Just… reschedule psilocybin?

Cannabis Law Report

However, our drug laws impede research and deny patients access to these highly effective medicines. Firstly, psychedelics are administered infrequently in controlled settings with up to only three treatments shown to produce long lasting benefits in clinical trials so far. Secondly, people report being healed.

article thumbnail

Vice Article: Australians Can Get a Medicinal Cannabis Prescription for Pretty Much Anything

Cannabis Law Report

This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. Using data from the Therapeutic Goods Administration (TGA) – Australia’s Special Access Scheme B, the researchers found the other two top reasons for prescriptions were pain and sleep disorders.

article thumbnail

UK: David Hardstaff And John Binns Write For Open Access Government Exploring Shifting Sands In The UK CBD Industry

Cannabis Law Report

One of the largest and arguably sustainable customer bases, however, is consumers with some sort of health or therapeutic need for which they are unable to access medicinal cannabis. One potential consequence of the FSA’s drive to rein in the UK’s CBD industry is reduced access to the previously available wide range of products.

Access 52
article thumbnail

Researchers Concerned About Whitewashing of Psychedelic-Assisted Mental Health Research

Cannabis Law Report

As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021.

article thumbnail

Understanding the Current Legal Status of Psychedelics in the United States

Cannabis Law Report

In a previous article, we explored one potential current opportunity for entrepreneurs interested in psychedelics and mycelium— producing non-psychoactive mushroom supplements. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*. WRITTEN BY: Vicente Sederberg LLP.